Nesiritide (Natrecor)
Overview
A recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide naturally produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), activating guanylyl cyclase and increasing intracellular cGMP to produce venous, arterial, and coronary vasodilation, natriuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic nervous systems.
Key Research Findings
FDA-approved in 2001 for acutely decompensated heart failure with dyspnea at rest. ASCEND-HF trial (2011) showed modest improvement in dyspnea but no reduction in mortality or rehospitalization, with trends toward worsening renal function and hypotension. Use has declined significantly in favor of other heart failure therapies. Remains available but relegated to second-line status by current guidelines.
Intravenous
FDA Approved
Interested in Nesiritide (Natrecor)?
Find a verified provider experienced with Nesiritide (Natrecor) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Nesiritide (Natrecor) ProviderRelated Peptides
Eptifibatide (Integrilin)
FDA ApprovedA synthetic cyclic heptapeptide modeled after the KGD (Lys-Gly-Asp) disintegrin sequence found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a potent, reversible glycoprotein IIb/IIIa receptor antagonist that blocks the final common pathway of platelet aggregation by preventing fibrinogen and von Willebrand factor binding to activated platelets.
Angiotensin II (Giapreza)
FDA ApprovedA synthetic form of the endogenous octapeptide angiotensin II, the primary effector of the renin-angiotensin system. Angiotensin II acts on AT1 receptors on vascular smooth muscle to produce potent vasoconstriction, and on the adrenal cortex to stimulate aldosterone release. Exogenous administration raises blood pressure in vasodilatory shock refractory to conventional vasopressors by restoring vascular tone through a mechanism complementary to catecholamine vasopressors.